<DOC>
	<DOC>NCT02970292</DOC>
	<brief_summary>To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia</brief_summary>
	<brief_title>Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>1. Adults patients, aged 18 years and above 2. A clinical diagnosis of schizophrenia with a minimum duration of 1 year 3. Has had equal to or less than 10 years of treatment with an antipsychotic 4. The main background antipsychotic with which the subject is being treated must be one of the antipsychotics listed below: Aripiprazole Risperidone Olanzapine Lurasidone Cariprazine Brexpiprazole Asenapine Risperidone longacting injection Aripiprazole longacting injectables: Abilify Maintena® Aristada® 5. Has had a partial but inadequate response to antipsychotic treatment 6. Has a history of response to antipsychotic treatment other than clozapine 1. Patient has a psychiatric disorder other than schizophrenia 2. Patient has a history of resistance to antipsychotic treatment 3. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program 4. Patient has had a myocardial infarction in the last six months 5. Patient is taking a medication or drug that prolongs the QT interval or has a history or symptoms of long QT syndrome Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all prespecified entry criteria).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>